Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

New therapy aspects for myeloid chronic lymphoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.12.13
Views: 3711

Dr Simon Rule, Prof Martin Dreyling, Prof Olivier Hermine

Speaking to ecancer from the 55th meeting of the American Society of Haematology (ASH) in New Orleans, USA, Dr Simon Rule, Derriford Hospital, Plymouth, UK; Prof Martin Dreyling, University Hospital Grosshadern, Munich; and Prof Olivier Hermine, Paris, France, discuss new aspects of therapies for myeloid chronic lymphoma (MCL), especially combination therapies.

Dr Rule discusses the role of a multimodal approach, and suggests that ibrutinib is promising as a monotherapy but may be more useful as part of an integrated approach.  Prof Dreyling introduces a new theme, that has appeared at ASH 2013– that therapies should not be too specific.  Less-specific compounds may be more effective in reducing, or even preventing, therapy resistance due to the fact that MCL is not caused by just one genetic lesion, so can not be treated with a one-hit specific therapy; therapies must be combined in an intelligent way to overcome the disease – to get long, ongoing remission, chemotherapy needs to be augmented with combinations of newer drugs.

Dr Rule and Prof Dreyling discuss the future for MCL, and agree that more compounds are being discovered than there are patients available to test them on. Clinical research must only focus on those drugs that have a real possibility of a positive outcome. The ‘pick a winner’ trial design is deemed an attractive option for phase II trials.

The panel concludes with a brief discussion of trials presented at ASH 2013, and the advantages and disadvantages of radiotherapy compared with drug therapies.

Read our ASH 2013 conference report for free.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation